Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | FURIN | P09958 | 3/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | NMT2 | O60551 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24141113 | 0.93 | SMN1; SMN2 (0.44) | SMN1; SMN2HPGDHTTALDH1A1POLB | |
| SCHEMBL15870198 | 0.93 | SMN1; SMN2 (0.43) | SMN1; SMN2HPGDHTTALDH1A1POLB | |
| SCHEMBL21120393 | 0.92 | SMN1; SMN2 (0.43) | SMN1; SMN2HPGDHTTALDH1A1POLB | |
| SCHEMBL17993320 | 0.92 | SMN1; SMN2 (0.43) | SMN1; SMN2HPGDHTTALDH1A1POLB | |
| SCHEMBL28051813 | 0.89 | C3AR1 (0.40) | POLBNOD1EPHX2C3AR1FNTA | |
| SCHEMBL2801888 | 0.89 | C3AR1 (0.40) | POLBNOD1EPHX2C3AR1FNTA | |
| SCHEMBL22134344 | 0.89 | C3AR1 (0.40) | POLBNOD1EPHX2C3AR1FNTA | |
| SCHEMBL16925642 | 0.89 | C3AR1 (0.40) | POLBNOD1EPHX2C3AR1FNTA | |
| SCHEMBL19776914 | 0.86 | FNTA (0.40) | POLBNOD1EPHX2C3AR1FNTA | |
| SCHEMBL2715793 | 0.84 | NMT2 (0.49) | NOD1EPHX2C3AR1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630732-B1 | METHOD AND MOLECULES | MEDIMMUNE LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20200206359-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206359-A1 | Method And Molecules | PAICS, EPCAM, SQLE | SMN1; SMN2 3495/4885HPGD 668/4885HTT 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.